R. Buhl (Mainz, Germany), M. Bonini (Rome, Italy)
Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy.
M. Panagiotou (Athens, Greece), N. Koulouris (Athens, Greece), A. Koutsoukou (Athens, Greece), M. Tsami (Athens, Greece), E. Syrigou (Athens, Greece), N. Rovina (Athens, Greece)
|  |
Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation
S. Gai (Shanghai, China), Y. Wan (Shanghai, China), H. Cao (Shanghai, China), M. Zhu (Shanghai, China), G. Li (Shanghai, China)
|  |
One year of mepolizumab in severe asthma in Italy: efficacy and safety
D. Bagnasco (Genoa, Italy), M. Caminati (Verona, Italy), F. Menzella (Regio Emilia, Italy), M. Milanese (Pietra Ligure, Italy), A. Bragantini (Genoa, Italy), G. Rolla (Turin, Italy), C. Lombardi (Brescia, Italy), C. Bucca (Turin, Italy), E. Heffler (Milan, Italy), G. Paoletti (Milan, Italy), C. Caruso (Rome, Italy), G. Guida (Turin, Italy), M. Bonavia (Arenzano, Italy), G. Senna (Verona, Italy), G. Canonica (Milan, Italy), G. Passalacqua (Genoa, Italy)
| |
Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis
B. Kent (London, United Kingdom), G. D'Ancona (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Green (London, United Kingdom), J. Kavanagh (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), C. Roxas (London, United Kingdom), S. Agarwal (London, United Kingdom), D. Jackson (London, United Kingdom)
| |
Changing between anti-IL5 and anti-IL5 receptor treatments. A real-life study
A. Bjerrum (Aarhus, Denmark), T. Skjold (Aarhus, Denmark), H. Andersen (Aarhus, Denmark), L. Pedersen (Aarhus, Denmark), J. Schmid (Aarhus, Denmark)
| |
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
S. Korn (Mainz, Germany), L. Ehrhard (Mainz, Germany), S. Voigt (Mainz, Germany), R. Buhl (Mainz, Germany)
| |
Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma
A. Gruber (Rueil Malmaison, France), C. Taillé (Paris, France), P. Chanez (Marseille, France), G. Devouassoux (Lyon, France), A. Didier (Toulouse, France), C. Pison (Grenoble, France), G. Garcia (Paris, France), A. Bourdin (Montpellier, France), C. Pribil (Rueil Malmaison, France), M. Humbert (Paris, France)
| |
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
D. Laorden Escudero (Madrid, Spain), E. Zamarrón De Lucas (Madrid, Spain), D. Romero Ribate (Madrid, Spain), J. Fernández Lahera (Madrid, Spain), F. García Río (Madrid, Spain), C. Villasante Fernández (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain), S. Quirce Gancedo (Madrid, Spain), J. Padilla Brito (Madrid, Spain), P. Barranco Sanz (Madrid, Spain)
| |
Switch Omalizumab – Mepolizumab: real life experience
D. Bagnasco (Genoa, Italy), F. Menzella (Reggio Emilia, Italy), M. Caminati (Verona, Italy), M. Bonavia (Arenzano, Italy), G. Guida (Turin, Italy), C. Caruso (Rome, Italy), G. Passalacqua (Genoa, Italy)
| |
Characterization of omalizumab partitioning in the nasal mucosa of patients
R. Zhu (South San Francisco, United States of America), R. Owen (South San Francisco, United States of America), T. Staton (South San Francisco, United States of America), K. Peng (South San Francisco, United States of America), C. Huang (South San Francisco, United States of America), M. Bremer (South San Francisco, United States of America), N. Meshgin (South San Francisco, United States of America), P. Banerjee (South San Francisco, United States of America), R. Bauer (South San Francisco, United States of America), F. Cai (South San Francisco, United States of America)
| |
Systematic review and MAIC of OCS reduction with biologic asthma treatments
A. Bourdin (Montpellier, France), D. Husereau (Alberta, Canada), N. Molinari (Montpellier, France), S. Golam (Gothenburg, Sweden), M. Siddiqui (Chandigarh, India), L. Lindner (Barcelona, Spain), X. Xu (Gaithersburg, United States of America)
| |
Benralizumab treatment and SARP cluster analysis
E. Bleecker (Tucson, United States of America), X. Li (Tucson, United States of America), P. Newbold (Gaithersburg, United States of America), I. Hirsch (Gaithersburg, United States of America), H. Li (Tucson, United States of America), J. Zangrilli (Gaithersburg, United States of America), M. Goldman (Gaithersburg, United States of America), D. Meyers (Tucson, United States of America)
| |
The anti-IL-13 biologic tralokinumab did not alter expression of T2 and T17 transcription factors GATA3 and RORyT in bronchial biopsies
L. Chachi (Leicester, United Kingdom), R. Russell (Leicester, United Kingdom), S. Diver (Leicester, United Kingdom), G. Elliott (Leicester, United Kingdom), J. Sousa (Leicester, United Kingdom), C. Emson ( Gaithersburg, United States of America), J. Griffiths ( Gaithersburg, United States of America), P. Newbold ( Gaithersburg, United States of America), G. Colice ( Gaithersburg, United States of America), C. Brightling (Leicester, United Kingdom)
| |
Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma
L. Chachi (Leicester, United Kingdom), S. Diver (Leicester, United Kingdom), H. Kaul ( Vancouver , Canada), P. Nisa (Leicester, United Kingdom), P. Newbold (Gaithersburg, United States of America), C. Brightling (Leicester, United Kingdom)
| |
The effect of anti-IL-5 therapy on sputum cells and cytokines in asthmatics
T. Decaesteker (Leuven, Belgium), S. Bos (Leuven, Belgium), S. Seys (Leuven, Belgium), D. Bullens (Leuven, Belgium), L. Dupont (Leuven, Belgium)
| |
FEV1 early response (ER) and super-response (SR) with reslizumab (RES) in eosinophilic asthma
J. Virchow (Rostock, Germany), L. Hickey (Malvern, PA, United States of America), M. Garin (Malvern, PA, United States of America)
| |
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics
S. Principe (Pa, Italy), L. Calzetta (Rome, Italy), A. Benfante (Pa, Italy), P. Rogliani (Rome, Italy), N. Scichilone (Pa, Italy)
| |
Early treatment response may predict long-term mepolizumab benefit in severe asthma
J. Kroes (Leeuwarden, Netherlands), M. Wiegman (Leeuwarden, Netherlands), A. Van Der Meer (Leeuwarden, Netherlands), R. Gijtenbeek (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), S. Zielhuis (Leeuwarden, Netherlands), E. Van Roon (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)
| |